Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations, namely JAK2, CALR, and MPL mutations. The identification of “high-molecular-risk” (HMR) mutations, which may hold prognostic relevance, by next-generation sequencing may aid in the determination of clonality, especially in patients lacking one of the three “driver” mutations. Some prognostic models, which take into account HMR mutations, have refined the risk stratification of patients with MPN. Health care providers are challenged to stay abreast of new developments in the field that may help inform clinical decision-making.
Target Audience
This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Discuss how “driver” mutations and clonal markers are incorporated in the WHO diagnostic criteria.
- Describe the prognostic relevance of “high-molecular-risk” mutations in managing patients with myeloproliferative neoplasms (MPN).
- Identify which prognostic models include the presence of high-molecular-risk mutations.
Aaron T. Gerds, MD, MS
Cleveland Clinic Taussig Cancer Institute/Case Comprehensive Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Presenting Faculty
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Aaron T. Gerds, MD, MS
AbbVie, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Constellation Pharmaceuticals: Consulting Fee
CTI BioPharma Corp.: Consulting Fee
Kartos Therapeutics, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
PharmaEssentia Corporation: Consulting Fee
Promedior, Inc.: Consulting Fee
Sierra Oncology: Consulting Fee
Moderator
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Andrew T. Kuykendall, MD
AbbVie, Inc.: Honoraria
Blueprint Medicines: Grant/Research Support; Honoraria; Product/Speakers Bureau
Celgene Corporation: Consulting Fee; Grant/Research Support; Honoraria; Product/Speakers Bureau
CTI BioPharma Corp.: Honoraria
Incyte Corporation: Product/Speakers Bureau; Scientific Advisor
Novartis Pharmaceuticals Corporation: Honoraria: Product/Speakers Bureau
PharmaEssentia Corporation: Honoraria; Scientific Advisor
Prelude Therapeutics: Grant/Research Support; Scientific Advisor
Protagonist Therapeutics, Inc.: Consulting Fee; Honoraria; Product/Speakers Bureau
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-117-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing